Breaking News Instant updates and real-time market news.

XNET

Xunlei

$5.79

0.07 (1.22%)

, AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

08:45
11/14/19
11/14
08:45
11/14/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Xunlei (XNET) 29.96% +0.47, AMC Entertainment (AMC) 3.01% +0.39, Canopy Growth (CGC) 19.48% +0.34, NortonLifeLock (NLOK) 0.59% +0.26, Facebook (FB) 0.50% +0.25, Hilton Grand Vacations (HGV) 0.70% +0.22, Hexo Corp (HEXO) 55.22% +0.22, ADT (ADT) 19.86% +0.21, Anheuser Busch (BUD) 2.04% +0.21, and ABB (ABB) 0.89% +0.18.

XNET

Xunlei

$5.79

0.07 (1.22%)

AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

CGC

Canopy Growth

$18.52

-0.69 (-3.59%)

NLOK

NortonLifeLock

$24.57

0.36 (1.49%)

FB

Facebook

$193.20

-1.27 (-0.65%)

HGV

Hilton Grand Vacations

$35.24

-0.07 (-0.20%)

HEXO

Hexo

$1.99

-0.14 (-6.59%)

ADT

ADT Inc.

$8.36

0.66 (8.57%)

BUD

AB InBev

$79.37

0.28 (0.35%)

ABB

ABB

$21.93

0.11 (0.50%)

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 27

    Feb

XNET Xunlei
$5.79

0.07 (1.22%)

AMC AMC Entertainment
$8.77

-0.51 (-5.50%)

08/09/19
RILY
08/09/19
NO CHANGE
Target $22
RILY
Buy
AMC Entertainment added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Eric Wold added AMC Entertainment to his firm's Alpha Generator list while boosting his price target for the shares to $22 from $19. Theater enhancements and AMC's Stubs A-List is driving profitable market share gains, Wold tells investors in a research note. He keeps a Buy rating on the shares.
08/29/19
IMPC
08/29/19
NO CHANGE
Target $451
IMPC
Outperform
Netflix price target lowered to $451 from $458 at Imperial Capital
Imperial Capital analyst David Miller lowered his price target for Netflix (NFLX) to $451 from $458 while maintaining an Outperform rating on the shares. The analyst reduced his fiscal 2019 EBITDA and earnings slightly due to higher marketing expense and higher technology costs overseas. His fiscal 2020 estimates also decline modestly to account for higher production expenses in Europe. Various trade publications on Tuesday reported that Netflix was unable to strike a wide-release theatrical arrangement for its upcoming organized crime drama, The Irishman, Miller points out. Even by Netflix standards, the film is "extraordinarily expensive," costing as much as $200M in total production expense, adds the analyst. The market responded by sending shares of Netflix down 1.3%, and shares of Cinemark (CNK) and AMC Entertainment (AMC) down 1.1% and 3.8%, respectively, he notes. Miller believes the exhibitors simply want Netflix to play by the same rules that every other studio uses in the theatrical window, and that is, at least a 90-day exclusive window before the film hits the various ancillary frames used by the studio system.
10/07/19
IMPC
10/07/19
NO CHANGE
Target $21
IMPC
Outperform
AMC Entertainment price target lowered to $21 from $23 at Imperial Capital
Imperial Capital analyst David Miller lowered his price target for AMC Entertainment to $21 from $23 while maintaining an Outperform rating on the shares.
10/22/19
MKMP
10/22/19
NO CHANGE
Target $28
MKMP
Buy
Imax a 'misunderstood, underappreciated' asset, says MKM Partners
MKM Partners analyst Eric Handler is keeping his Buy rating and $28 price target on Imax (IMAX), saying the stock has been "unjustly" punished for the overall 2019 box office weakness and China exposure. The analyst contends however that the company is still on track to grow its own box office sales by 10% this year, while its China box office revenue is up 20% year-to-date. Handler adds that despite these positive trends and a much lower capital intensity relative to traditional theatres, Imax valuation is in-line with AMC Entertainment (AMC) and Cinemark (CNK).
CGC Canopy Growth
$18.52

-0.69 (-3.59%)

11/05/19
11/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HBT Financial (HBT) initiated with an Outperform at Raymond James as well as Keefe Bruyette and a Neutral at JPMorgan. 2. Canopy Growth (CGC) initiated with a Neutral at Cantor Fitzgerald. 3. uniQure (QURE) initiated with an Outperform at Credit Suisse. 4. SkyWest (SKYW) initiated with an Overweight at Stephens. 5. Anika Therapeutics (ANIK) initiated with a Sell at BWS Financial. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
CANT
11/05/19
INITIATION
CANT
Neutral
Canopy Growth initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Canopy Growth with a Neutral rating and C$27 price target. s. Canopy has the lowest gross margin among the peer group and despite all its medical intellectual property, it "seems to have dropped the ball" in Canada medical, says the analyst.
11/05/19
BOFA
11/05/19
NO CHANGE
BOFA
BofA says Mexico cannabis legalization 'still in play' in 2020 after extension
BofA Merrill Lynch analyst Christopher Carey noted that Mexico's Supreme Court has granted an extension until April 30, 2020 for Congress to legalize all forms of cannabis, writing in its decision that considering the complexity of the issue it grants the extension "exceptionally and for one time only." He views this as an important development for the industry since, in addition to opening a potentially large market, it will put even more pressure on U.S. federal action as the country will potentially "place the US between 2 of only 3 countries in the world to have legalized cannabis for recreational use." 9% of Mexico's population of 131M is estimated to have consumed cannabis in 2018 and the legal market could be worth $1B by 2024, according to BDS Analytics, noted Carey. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Trulieve Cannabis (TCNNF).
11/11/19
MKMP
11/11/19
NO CHANGE
MKMP
Canopy Growth, Aurora Cannabis price targets lowered at MKM Partners
MKM Partners analyst Bill Kirk kept his Neutral rating on Canopy Growth (CGC) while lowering its price target to CAD30 from CAD33 and also kept his Sell rating with an unchanged CAD3.50 price target on Aurora Cannabis (ACB) ahead of their earnings reports this Thursday. The analyst says that neither company is expected to show much improvement on the top line, with inventory held at provinces weighing on shipments, pricing coming down, and the price premium relative to "illicit channels" widening. Kirk adds that the likely earnings disappointment may result in the bulls "revisiting the industry's path and pace toward profitability."
NLOK NortonLifeLock
$24.57

0.36 (1.49%)

11/06/19
LEHM
11/06/19
INITIATION
Target $27
LEHM
Equal Weight
NortonLifeLock reinstated with an Equal Weight at Barclays
Barclays analyst Saket Kalia reinstated coverage of NortonLifeLock with an Equal Weight rating and $27 price target. The analyst believes the company should be an execution story on removing $1.5B in stranded costs.
11/08/19
11/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated with a Neutral at UBS. 2. NortonLifeLock (NLOK) resumed with a Sector Perform at RBC Capital. 3. Manitex (MNTX) resumed with a Buy at Roth Capital. 4. Oneok (OKE) initiated with a Buy at Tudor Pickering. 5. II-VI (IIVI) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/19
RBCM
11/08/19
INITIATION
Target $25
RBCM
Sector Perform
NortonLifeLock resumed with a Sector Perform at RBC Capital
RBC Capital analyst Matthew Hedberg resumed coverage of NortonLifeLock with a Sector Perform rating and $25 price target. The analyst says the company beat on Q3 revenue with a "good quarter" following the completion of its Enterprise Security Assets sale to Broadcom earlier in the week. Hedberg adds that NortonLifeLock will have to focus on progress toward the elimination of "stranded costs" and wants to see more signs of execution before considering a more "aggressive" rating.
11/08/19
MZHO
11/08/19
NO CHANGE
Target $28
MZHO
Buy
NortonLifeLock valuation 'looks very attractive,' says Mizuho
Mizuho analyst Gregg Moskowitz says NortonLifeLock's valuation "looks very attractive" and that he recommends buying the shares. Guidance for proceeds from monetized assets was raised, and guidance for cash requirements on stranded costs was lowered, resulting in a "meaningfully positive cash flow variance," Moskowitz tells investors in a post-earnings research note. He keeps a Buy rating on NortonLifeLock with a $28 price target.
FB Facebook
$193.20

-1.27 (-0.65%)

11/04/19
SPHN
11/04/19
INITIATION
Target $250
SPHN
Overweight
Stephens starts Trade Desk at Overweight, touts model compared to Netflix, Roku
Stephens analyst Kyle Evans initiated coverage of Trade Desk (TTD) with an Overweight rating and $250 price target, stating that he believes investors should own the stock because the company has "a more distributed, defendable and profitable business model" than Netflix (NFLX) or Roku (ROKU) with fewer regulatory risks than Google (GOOGL) or Facebook (FB), although he added that the stock is "volatile and expensive." He sees the catalysts of connected TV tailwinds and international growth outweighing the risks of a premium multiple and the growth of ad-free streaming TV options, Evans added.
11/04/19
DAIW
11/04/19
UPGRADE
DAIW
Buy
Facebook upgraded to Buy from Outperform at Daiwa
11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
DAIW
11/05/19
UPGRADE
Target $250
DAIW
Buy
Daiwa upgrades Facebook to Buy, says earnings concerns 'largely alleviated'
Daiwa analyst Satoshi Tanaka last night upgraded Facebook to Buy from Outperform with a price target of $250, up from $235. The company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns," Tanaka tells investors in a research note. The analyst sees "clearer visibility" from 2020 as well as higher upside after the stock's recent pullback. Facebook's revenue growth slowdown is more moderate than previously anticipated while its guidance for total expenses remains within expectations, contends the analyst. He believes the "negative repercussions" stemming from the implementation of Europe's new data protection regulation and Facebook's data leak "controversy are clearer now that a year has passed." Concerns on the earnings front "have largely been alleviated," says Tanaka.
HGV Hilton Grand Vacations
$35.24

-0.07 (-0.20%)

09/25/19
JANY
09/25/19
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Hilton Grand Vacations to Neutral on valuation
As previously reported, Janney Montgomery Scott analyst Tyler Batory downgraded Hilton Grand Vacations to Neutral from Buy, stating that his rating change was "mostly" due to valuation as he thinks the risk/reward is more balanced following the New York Post article published last month about a potential takeout. Batory set a $36 fair value estimate on the shares, but sees 15% downside if a deal is not announced, adding that he thinks "it's difficult to know for sure whether HGV will be taken private or not."
09/25/19
09/25/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Liberty Global (LBTYA) downgraded to Equal Weight from Overweight at Barclays. 2. Borr Drilling (BORR) downgraded to Equal Weight from Overweight at Morgan Stanley. 3. Atlantic Union Bankshares (AUB) downgraded to Hold from Buy at Sandler O'Neill with analyst Casey Orr citing valuation. 4. Hilton Grand Vacations (HGV) downgraded to Neutral at Janney Montgomery Scott with analyst Tyler Batory saying his rating change was "mostly" due to valuation as he thinks the risk/reward is more balanced following the New York Post article published last month about a potential takeout. 5. Ultra Clean (UCTT) downgraded to Market Perform from Outperform at Cowen with analyst Karl Ackerman saying his field work in Asia suggests investor expectations for memory wafer fab equipment "may be inflated." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/19
NOMU
09/24/19
NO CHANGE
Target $33
NOMU
Neutral
Hilton Grand Vacations price target raised to $33 from $29 at Nomura Instinet
Nomura Instinet analyst Brian Dobson raised his price target for Hilton Grand Vacations to $33 from $29 to reflect a higher valuation multiple as the result of reports that the company is an acquisition candidate. However, the analyst believes the shares are fairly valued and that a meaningful acceleration in contract sales is unlikely in the near term. As such, he keeps a Neutral rating on Hilton Grand Vacations.
09/25/19
JANY
09/25/19
DOWNGRADE
JANY
Neutral
Hilton Grand Vacations downgraded to Neutral at Janney Montgomery Scott
HEXO Hexo
$1.99

-0.14 (-6.59%)

11/05/19
CANT
11/05/19
INITIATION
CANT
Underweight
Hexo initiated with an Underweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Hexo with an Underweight rating and C$2.40 price target. The company has "big ambitions," and some of its previously stated targets may have helped the stock, but its performance so far and announced plans to date "are not aligned with the vision," Zuanic tells investors in a research note.
10/30/19
ADAM
10/30/19
DOWNGRADE
ADAM
Hold
Hexo downgraded to Hold from Speculative Buy at Canaccord
Canaccord Genuity analyst Matt Bottomley downgraded Hexo to Hold from Speculative Buy with a price target of C$3.50.
10/29/19
ROTH
10/29/19
NO CHANGE
Target $2.5
ROTH
Neutral
Hexo price target cut to $2.50 from $3 at Roth Capital
Roth Capital analyst Scott Fortune cut his price target on Hexo to $2.50 from $3 after the company reported Q4 results and provided a "soft" guidance for Q1. Fortune, who also lowered his 2020 estimates for Hexo, noted that management cited lower than expected sell-through due to slower than anticipated retail store openings, "weak" specific product sales, and competitive pricing pressures. The analyst, who kept a Neutral rating on the stock, said he expects Canadian short-term negative pressure to remain and doesn't expect positive earnings per share or adjusted EBITDA until the end of 2020.
10/30/19
EGCP
10/30/19
DOWNGRADE
EGCP
Sell
Hexo downgraded to Sell from Neutral at Eight Capital
Eight Capital analyst Graeme Kreindler downgraded Hexo to Sell from Neutral.
ADT ADT Inc.
$8.36

0.66 (8.57%)

03/12/19
SBSH
03/12/19
DOWNGRADE
Target $8.25
SBSH
Neutral
ADT Inc. downgraded to Neutral from Buy at Citi
Cit downgraded ADT Inc. to Neutral from Buy and lowered its price target for the shares to $8.25 from $13. The firm sees a less certain free cash flow trajectory following ADT's Q4 results.
05/13/19
05/13/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) and Titan Machinery (TITN) downgraded to Neutral from Outperform at Baird. 2. Boot Barn (BOOT) downgraded to Hold from Buy at Pivotal Research with analyst Mitch Kummetz saying he sees a less favorable risk/reward at current share levels heading into the company's results on May 16. He does not see enough room for upside to his estimates, mainly because he believes oil and gas employment is becoming a "diminishing tailwind." 3. Shopify (SHOP) downgraded to Neutral from Buy at Guggenheim with analyst Ken Wong saying he sees upside potential as limited given the stock's current valuation, which he notes has now passed previous peak levels. 4. ADT Inc. (ADT) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. 5. 51job (JOBS) downgraded to Neutral from Buy at Citi with analyst Alicia Yap saying she believes weakening operating metrics, such as a faster rate of decline for active employer count and slower rate of growth of ARPU, may be signals of challenges for online recruitment revenue growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
MSCO
05/13/19
DOWNGRADE
Target $7
MSCO
Equal Weight
ADT Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Toni Kaplan downgraded ADT Inc. (ADT) to Equal Weight from Overweight as she has less confidence in the company's growth outlook following a recent AlphaWise survey conducted by the firm. The survey showed homeowners seem as inclined to buy DIY systems as ADT systems, that more ADT customers switched to DIY providers than she would have expected and that measure of brand preference for Amazon's (AMZN) Ring and Google's (GOOG) Nest were higher than for ADT, Kaplan explains. Given that the survey leads her to fear ADT may find it difficult to defend its market share, Kaplan lowered her price target on the stock to $7 from $9.
03/15/19
IMPC
03/15/19
NO CHANGE
Target $12
IMPC
Outperform
ADT Inc. price target lowered to $12 from $15 at Imperial Capital
Imperial Capital analyst Jeff Kessler lowered his price target for ADT Inc. to $12 from $15 saying "heavy" investment translated to reduced free cash flow guidance for 2019. The analyst, however, sees continued revenue growth for ADT and maintains an Outperform rating on the shares.
BUD AB InBev
$79.37

0.28 (0.35%)

11/01/19
RBCM
11/01/19
NO CHANGE
RBCM
Sector Perform
AB InBev price target lowered to EUR72 from EUR89 at RBC Capital
RBC Capital analyst James Edward Jones lowered his price target on AB InBev to EUR72 and kept his Sector Perform rating. The analyst warns that the company will struggle to grow its EIBT by more than mid-single digits and also believes that its margins have peaked while its U.S. market share loss has accelerated.
11/12/19
MAXM
11/12/19
DOWNGRADE
Target $16.5
MAXM
Hold
Craft Brew downgraded to Hold from Buy at Maxim
Maxim analyst Stephen Anderson downgraded Craft Brew (BREW) to Hold from Buy with a price target of $16.50, up from $16, after yesterday's announcement that the company agreed to be acquired by Anheuser-Busch Inbev (BUD) for $321M, or $16.50 per share. The analyst believes that a higher bid from a rival is unlikely.
10/28/19
GUGG
10/28/19
NO CHANGE
Target $106
GUGG
Buy
AB InBev should be bought, especially on weakness, says Guggenheim
Guggenheim analyst Laurent Grandet lowered his price target for AB InBev to $106 from $114 following the company's "softer than expected" Q3 results. The analyst, however, remains positive on the shares. He says AB InBev remains one of the "most attractive growth algorithms in the space" with continued optionality for acquisitions given the recently completed initial public offering in Asia Pacific. Grandet recommends investors accumulate shares, especially on weakness, and keeps a Buy rating on the name.
10/28/19
MACQ
10/28/19
NO CHANGE
Target $97
MACQ
Neutral
AB InBev price target lowered to $97 from $104 at Macquarie
Macquarie analyst Caroline Levy lowered her FY19, 20 and 21 EPS estimates for AB InBev following the company's disappointing Q3 results, stating that Brazil and Korea were the main drags but North America was also worse than expected. She prefers to remain sidelined on AB InBev and keeps a Neutral rating on the shares.
ABB ABB
$21.93

0.11 (0.50%)

03/04/19
DNBM
03/04/19
DOWNGRADE
DNBM
Hold
ABB downgraded to Hold from Buy at DNB Markets
07/26/19
VERT
07/26/19
UPGRADE
VERT
Hold
ABB upgraded to Hold from Sell at Vertical Research
08/01/19
SOCG
08/01/19
DOWNGRADE
SOCG
Hold
ABB downgraded to Hold from Buy at Societe Generale
01/28/19
BREN
01/28/19
DOWNGRADE
BREN
Sell
ABB downgraded to Sell from Hold at Berenberg
Berenberg analyst Simon Toennessen downgraded ABB to Sell saying recent money supply trends suggest the company's order growth could fall by double-digits. The analyst cut his price target for the shares to CHF 17.50 from CHF 21.

TODAY'S FREE FLY STORIES

04:00
12/09/19
12/09
04:00
12/09/19
04:00
General news
FX Action: USD-CAD has consolidated around 1.3250 »

FX Action: USD-CAD has…

03:20
12/09/19
12/09
03:20
12/09/19
03:20
General news
FX Update: The pound rallied to new highs »

FX Update: The pound…

03:05
12/09/19
12/09
03:05
12/09/19
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
12/09/19
12/09
03:05
12/09/19
03:05
General news
FOMC Forecast revisions »

FOMC Forecast revisions,…

03:05
12/09/19
12/09
03:05
12/09/19
03:05
General news
With or without a "phase one" deal »

With or without a…

PLMR

Palomar

20:27
12/08/19
12/08
20:27
12/08/19
20:27
Recommendations
Palomar analyst commentary at Keefe Bruyette »

Palomar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ASAZY

Assa Abloy

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Downgrade
Assa Abloy rating change at JPMorgan »

Assa Abloy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXEEY

Rexel

$0.00

(0.00%)

20:23
12/08/19
12/08
20:23
12/08/19
20:23
Upgrade
Rexel rating change at JPMorgan »

Rexel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$0.00

(0.00%)

20:22
12/08/19
12/08
20:22
12/08/19
20:22
Upgrade
Tate & Lyle rating change at Jefferies »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$0.00

(0.00%)

20:20
12/08/19
12/08
20:20
12/08/19
20:20
Upgrade
AU Optronics rating change at Morgan Stanley »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.22

0.115 (1.89%)

20:17
12/08/19
12/08
20:17
12/08/19
20:17
Upgrade
LG Display rating change at Morgan Stanley »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ETNB

89bio

$28.38

0.86 (3.13%)

20:16
12/08/19
12/08
20:16
12/08/19
20:16
Initiation
89bio initiated at Oppenheimer »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIOY

Acerinox

$0.00

(0.00%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Upgrade
Acerinox rating change at Jefferies »

Acerinox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

20:15
12/08/19
12/08
20:15
12/08/19
20:15
Conference/Events
Blueprint Medicines to hold an anlayst and investor event »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

TLSNY

Telia

$0.00

(0.00%)

20:14
12/08/19
12/08
20:14
12/08/19
20:14
Downgrade
Telia rating change at Jefferies »

Telia downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$67.25

1.705 (2.60%)

20:13
12/08/19
12/08
20:13
12/08/19
20:13
Recommendations
Arrowhead analyst commentary at Piper Jaffray »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$147.31

-2.56 (-1.71%)

20:08
12/08/19
12/08
20:08
12/08/19
20:08
Recommendations
Argenx analyst commentary at Stifel »

Argenx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

STC

Stewart

$43.16

0.28 (0.65%)

19:56
12/08/19
12/08
19:56
12/08/19
19:56
Downgrade
Stewart rating change at Keefe Bruyette »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAF

First American

$63.05

(0.00%)

19:55
12/08/19
12/08
19:55
12/08/19
19:55
Downgrade
First American rating change at Keefe Bruyette »

First American downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

PFSI

PennyMac Financial

$33.91

0.12 (0.36%)

19:54
12/08/19
12/08
19:54
12/08/19
19:54
Downgrade
PennyMac Financial rating change at Keefe Bruyette »

PennyMac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

18:40
12/08/19
12/08
18:40
12/08/19
18:40
Recommendations
Agios Pharmaceuticals analyst commentary at Piper Jaffray »

Agios' initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

18:34
12/08/19
12/08
18:34
12/08/19
18:34
Recommendations
Blueprint Medicines analyst commentary at Piper Jaffray »

Piper says 'jury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

18:29
12/08/19
12/08
18:29
12/08/19
18:29
Recommendations
Fate Therapeutics analyst commentary at Piper Jaffray »

FT500 data validates Fate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

18:05
12/08/19
12/08
18:05
12/08/19
18:05
Hot Stocks
Rocket says Phase 1 trial establishes feasibility of commercial Process B for FA »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

ARGX

Argenx

$147.31

-2.56 (-1.71%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

18:03
12/08/19
12/08
18:03
12/08/19
18:03
Recommendations
Argenx, Johnson & Johnson analyst commentary at Piper Jaffray »

Argenx data on…

ARGX

Argenx

$147.31

-2.56 (-1.71%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

  • 16

    Dec

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.